Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- 2024 Top Story in Oncology: Shifting the Scales — CDK4/6 Inhibitors and the Journey to Lower Recurrence Risk in Early-Stage Breast Cancer
- Efficacy of Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
- Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in Patients With Metastatic Breast Cancer and Cardiovascular Diseases
- Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer
- Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups
- Efficacy of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab Regimen for Treating CNS Metastases in Patients With HER2+ Breast Cancer
- Safety of Alpelisib Combined With Capecitabine in Patients With HER2− Metastatic Breast Cancer
- Outcomes of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and Clinical Subgroups
- Outcomes of Trastuzumab–Deruxtecan Therapy in Patients With HER2+ Breast Cancer and Active Brain Metastases
- Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for the Second-Line and Later-Line Treatment of Metastatic TNBC in the US